Search by Drug Name or NDC
NDC 52652-3001-01 Qbrelis 1 mg/mL Details
Qbrelis 1 mg/mL
Qbrelis is a ORAL SOLUTION in the HUMAN PRESCRIPTION DRUG category. It is labeled and distributed by Azurity Pharmaceuticals, Inc.. The primary component is LISINOPRIL.
MedlinePlus Drug Summary
Lisinopril is used alone or in combination with other medications to treat high blood pressure in adults and children 6 years of age and older. It is used in combination with other medications to treat heart failure. Lisinopril is also used to improve survival after a heart attack. Lisinopril is in a class of medications called angiotensin-converting enzyme (ACE) inhibitors. It works by decreasing certain chemicals that tighten the blood vessels, so blood flows more smoothly and the heart can pump blood more efficiently. High blood pressure is a common condition and when not treated, can cause damage to the brain, heart, blood vessels, kidneys, and other parts of the body. Damage to these organs may cause heart disease, a heart attack, heart failure, stroke, kidney failure, loss of vision, and other problems. In addition to taking medication, making lifestyle changes will also help to control your blood pressure. These changes include eating a diet that is low in fat and salt, maintaining a healthy weight, exercising at least 30 minutes most days, not smoking, and using alcohol in moderation.
Related Packages: 52652-3001-01Last Updated: 11/30/2022
MedLinePlus Full Drug Details: Lisinopril
Product Information
| NDC | 52652-3001 |
|---|---|
| Product ID | 52652-3001_39d16ba9-53e0-4052-8a27-61e75de1528a |
| Associated GPIs | 36100030002020 |
| GCN Sequence Number | 076442 |
| GCN Sequence Number Description | lisinopril SOLUTION 1 MG/ML ORAL |
| HIC3 | A4D |
| HIC3 Description | ANTIHYPERTENSIVES, ACE INHIBITORS |
| GCN | 41984 |
| HICL Sequence Number | 000132 |
| HICL Sequence Number Description | LISINOPRIL |
| Brand/Generic | Brand |
| Proprietary Name | Qbrelis |
| Proprietary Name Suffix | n/a |
| Non-Proprietary Name | lisinopril |
| Product Type | HUMAN PRESCRIPTION DRUG |
| Dosage Form | SOLUTION |
| Route | ORAL |
| Active Ingredient Strength | 1 |
| Active Ingredient Units | mg/mL |
| Substance Name | LISINOPRIL |
| Labeler Name | Azurity Pharmaceuticals, Inc. |
| Pharmaceutical Class | Angiotensin Converting Enzyme Inhibitor [EPC], Angiotensin-converting Enzyme Inhibitors [MoA] |
| DEA Schedule | n/a |
| Marketing Category | NDA |
| Application Number | NDA208401 |
| Listing Certified Through | 2024-12-31 |
Package
NDC 52652-3001-01 (52652300101)
| NDC Package Code | 52652-3001-1 |
|---|---|
| Billing NDC | 52652300101 |
| Package | 150 mL in 1 BOTTLE (52652-3001-1) |
| Marketing Start Date | 2016-08-29 |
| NDC Exclude Flag | N |
| Pricing Information | |
| Price Per Unit | 4.03654 |
| Pricing Unit | ML |
| Effective Date | 2024-01-01 |
| NDC Description | QBRELIS 1 MG/ML SOLUTION |
| Pharmacy Type Indicator | C/I |
| OTC | N |
| Explanation Code | 4, 5 |
| Classification for Rate Setting | B |
| As of Date | 2024-02-21 |